Join
Live feed
·
PRReleasevia Quantisnow
EyePoint Inc. logo

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy

ByQuantisnow·Wall Street's wire, on your screen.
EYPT· EyePoint Inc.
Industrials

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EYPT (EyePoint Inc.) and more on Quantisnow.